|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Incyte Corporation |
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00674479 |
The goal of this clinical research study is to learn if INCB018424 can help to control advanced hematological malignancies. The safety of this drug will also be studied.
Optional Procedures: You will be asked to allow extra blood to be drawn for pharmacokinetic (PK) testing. PK testing measures the amount of study drug in the body at different time points.
You will be asked to allow extra blood to be drawn for pharmacodynamic (PD) testing. PD testing is used to look at how the study drug in your body may affect the disease.
Condition | Intervention | Phase |
Acute Myeloid Leukemia Acute Lymphocytic Leukemia Myelodysplastic Syndrome Chronic Myelogenous Leukemia |
Drug: INCB018424 |
Phase II |
MedlinePlus related topics: | Cancer Leukemia, Adult Acute Leukemia, Adult Chronic |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Study of INCB018424 in Patients With Advanced Hematologic Malignancies |
Estimated Enrollment: | 120 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | May 2011 |
Estimated Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental
INCB018424
|
Drug: INCB018424
INCB018424 - 25 mg po twice daily.
|
Show Detailed Description |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Farhad Ravandi-Kashani, M.D. | 713/745-0394 | fravandi@mdanderson.org |
United States, Texas | |||||
The University of Texas M.D. Anderson Cancer Center | Recruiting | ||||
Houston, Texas, United States, 77030 | |||||
Contact: Farhad Ravandi-Kashani, M.D. 713-745-0394 fravandi@mdanderson.org | |||||
Principal Investigator: Farhad Ravandi-Kashani, M.D. |
M.D. Anderson Cancer Center |
Incyte Corporation |
Principal Investigator: | Farhad Ravandi-Kashani, M.D. | 713/745-0394 |
M.D. Anderson's Website 
  |
Responsible Party: | The University of Texas M. D. Anderson Cancer Center ( Farhad Ravandi-Kashani, M.D./Associate Professor ) |
Study ID Numbers: | 2007-0925 |
First Received: | May 5, 2008 |
Last Updated: | July 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00674479 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
|